Ophthalmology Times: January/February 2025

Neurologist warns about recurrent optic neuritis attacks.

Survey examines experiences and perceptions of patients living with GA.

Inflammation and scarring are the primary obstacles with pirfenidone.

Sophisticated programs require an evolving mindset.

These tools help fill a gap that current technologies cannot achieve as effectively.

Ophthalmologist offers insights into the value of technology in diabetic retinopathy.

Monofocal IOLs, along with advanced phacoemulsification technology, offer tailored solutions.

Shameema Sikder, MD; and T. Y. Alvin Liu, MD, highlight the technology’s role in bridging challenges and successes for clinical practice.

Clinician highlights a novel complication of atropine treatment in a teenage patient.

Advancements in drug durability and patient care are closing treatment gaps.

From cytokine pathways to genomics, Shree Kurup, MD, highlights new approaches for managing diabetic retinopathy and combating systemic inflammation.

Patients’ near visual needs is important when prescribing medications for glaucoma treatment

Real-world scenarios showcase a shift in treatment paradigms

As Ophthalmology Times celebrates 50 years of publication and the Wilmer Eye Institute marks 100 years of academic leadership, Peter J. McDonnell, MD, reflects on their shared commitment to helping ophthalmologists improve patient outcomes.